Tatja Hirvikoski, PhD, Department of Women's and Children's Health, Pediatric Neuropsychiatry Unit, Center for Neurodevelopmental Disorders at Karolinska Institutet (KIND), Karolinska Institutet, Stockholm, Sweden and Habilitation and Health, Stockholm County Council, Sweden; Ellenor Mittendorfer-Rutz, PhD, Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden; Marcus Boman, BSc, Henrik Larsson, PhD, Paul Lichtenstein, PhD, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Sven Bölte, PhD, Department of Women's and Children's Health, Pediatric Neuropsychiatry Unit, Center for Neurodevelopmental Disorders at Karolinska Institutet (KIND), Karolinska Institutet, Stockholm and Division of Child and Adolescent Psychiatry, Stockholm County Council, Sweden
Tatja Hirvikoski, PhD, Department of Women's and Children's Health, Pediatric Neuropsychiatry Unit, Center for Neurodevelopmental Disorders at Karolinska Institutet (KIND), Karolinska Institutet, Stockholm, Sweden and Habilitation and Health, Stockholm County Council, Sweden; Ellenor Mittendorfer-Rutz, PhD, Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden; Marcus Boman, BSc, Henrik Larsson, PhD, Paul Lichtenstein, PhD, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Sven Bölte, PhD, Department of Women's and Children's Health, Pediatric Neuropsychiatry Unit, Center for Neurodevelopmental Disorders at Karolinska Institutet (KIND), Karolinska Institutet, Stockholm and Division of Child and Adolescent Psychiatry, Stockholm County Council, Sweden.
Br J Psychiatry. 2016 Mar;208(3):232-8. doi: 10.1192/bjp.bp.114.160192. Epub 2015 Nov 5.
Mortality has been suggested to be increased in autism spectrum disorder (ASD).
To examine both all-cause and cause-specific mortality in ASD, as well as investigate moderating role of gender and intellectual ability.
Odds ratios (ORs) were calculated for a population-based cohort of ASD probands (n = 27,122, diagnosed between 1987 and 2009) compared with gender-, age- and county of residence-matched controls (n = 2,672,185).
During the observed period, 24,358 (0.91%) individuals in the general population died, whereas the corresponding figure for individuals with ASD was 706 (2.60%; OR = 2.56; 95% CI 2.38-2.76). Cause-specific analyses showed elevated mortality in ASD for almost all analysed diagnostic categories. Mortality and patterns for cause-specific mortality were partly moderated by gender and general intellectual ability.
Premature mortality was markedly increased in ASD owing to a multitude of medical conditions.
自闭症谱系障碍(ASD)患者的死亡率被认为有所增加。
研究 ASD 患者的全因死亡率和死因特异性死亡率,并探讨性别和智力能力的调节作用。
对 1987 年至 2009 年间诊断的 ASD 先证者(n=27122)的基于人群的队列与性别、年龄和居住地相匹配的对照组(n=2672185)进行比较,计算比值比(ORs)。
在观察期间,普通人群中有 24358 人(0.91%)死亡,而 ASD 患者的相应数字为 706 人(2.60%;OR=2.56;95%CI 2.38-2.76)。对几乎所有分析的诊断类别进行的死因特异性分析显示,ASD 患者的死亡率升高。死亡率和死因特异性死亡率模式部分受到性别和一般智力能力的调节。
由于多种医疗状况,ASD 患者的过早死亡率显著增加。